Increased AXL expression has been detected in a variety of solid tumors (e.g., prostate cancer, breast cancer, osteosarcoma, etc.)and hematological malignancies including chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma and mantle cell lymphoma. Here, AXL is linked to prostate cancer.